JPMorgan analyst Anupam Rama downgraded Day One Biopharmaceuticals (DAWN) to Neutral from Overweight with a $21.50 price target after the company announced an agreement under which Servier will acquire it for $21.50 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
- Day One Biopharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
- Day One Biopharma Earnings Call Highlights Ojemda Surge
- Hold Rating on Day One Biopharmaceuticals as Servier’s $2.5 Billion Takeout Caps Upside at $21.50 Target
- Midday Fly By: Rising oil prices, falling employment sink stocks